Safety and efficacy of anlotinib in patients with unresectable or metastatic bone and soft-tissue sarcomas:a retrospective institution study
10.3781/j.issn.1000-7431.2023.2302-0085
- VernacularTitle:单药安罗替尼对不可切除或晚期骨与软组织肿瘤的疗效及安全性研究
- Author:
Lina PANG
1
;
Shengli ZHANG
;
Xiaoke ZHANG
;
Shuai GONG
;
Liye WANG
;
Wei HE
Author Information
1. 郑州大学第一附属医院肿瘤科,河南 郑州 450052
- Keywords:
Bone and soft-tissue sarcoma;
Anlotinib;
Prognosis;
Efficacy;
Adverse event
- From:
Tumor
2023;43(9):710-719
- CountryChina
- Language:Chinese
-
Abstract:
Objective:This study aims to analyze the efficacy and safety of anlotinib in the real world for patients with unresectable or metastatic bone and soft-tissue sarcomas(STSs). Methods:Clinical data of 124 patients with unresectable or metastatic bone and STSs treated with anlotinib in the First Affiliated Hospital of Zhengzhou University from January 2018 to December 2020 were retrospectively analyzed.Information on age,sex,performance status,lines of anlotinib,surgical history,reduction of anlotinib,adverse reaction,metastatic site,tumor location,pathological subtypes and combination chemotherapy was collected and analyzed.The objective response rate(ORR)and disease control rate(DCR)was analyzed for short-term efficacy.Kaplan-Meier method was performed for survival analysis,and the evaluation indexes were median progression-free survival(mPFS)and median overall survival(mOS). Results:The main pathological subtypes of 124 patients were Synovial sarcoma(SS),Leiomyosarcoma(LMS),liposarcoma(LPS).The median age was 48.5 years(9-83 years).The ORR and DCR of anlotinib used in first-line therapy were 26.8％and 82.1％,but in second-line therapy and beyond,the ORR and DCR only were 5.9％and 64.7％.There were improvement in mPFS and mOS with anlotinib in first-line therapy compared to second-line therapy and beyond(mPFS:22.0 months vs 7.0 months,P=0.001;mOS:51.0 months vs 32.0 months,P=0.035).Adverse reactions of anlotinib were well tolerated,and the main grades of adverse reactions were grade Ⅰ and Ⅱ.No new anlotinib-related adverse reactions were identified. Conclusion:Anlotinib has shown a definite effect in the treatment of unresectable or metastatic bone and STSs.The adverse events of anlotinib are minor and well tolerated,and the efficacy of first-line treatment is better.
